I
amDr.ChristosChryssafis,fromtheKnappschaftsEye Clinic,Sulzbach,Saar,Germany.Iwritetopresentthe results of our studyaboutanintensifiedintravitreal bevacizumab(IVB)injectionsregimefortype1and2 idiopathicmaculartelangiectasia (IMT).Treatmentby thermallaser photocoagulation,photodynamictherapy, intravitrealtriamcinolonandretinalsurgerywasnotvery successful [1] [2] andnoneofthesetreatmentmodalitieshaveyet beenacceptedasagoldstandard.Vascularendothelial growthfactor(VEGF)issupposedtoplayanimportantrole inthepathogenesisandnaturalcourseofIMT [3] .Optimal schemeandtreatmentdurationofanti-VEGFtherapyfor IMTisunknown,especiallywithregardtolong-term follow-up [1] [2] 4] . [5] [6] andforpatientswithnonproliferativetype2IMT [1, [7] [8] [9] .Other studiescontradictingourresultsexistandshowedno morphologicalandfunctionalsignificantbenefitoftheuseof repeatedanti-VEGFtreatmentinIMT [4, 10] . ItislikelythatpatientswithIMTtype1withpronounced macularedemafromleakytelangiectasismaybenefit functionally andmorphologicallyfromintravitreal anti-VEGFinjections [5] reportedsimilarresults.Ourstudy indicatesthatthisbenefitcanbesustainedoveraquitelonger periodof40mo.Takayama [10] forexampleproposed thatIVBdidnotimprovevisualacuityorthicknessintype1 IMTandtype2respectively.Comparedtoourstudy,the numberofeyesincluded (5eyes)andtheshorterfollowup perior(12mo)couldexplainthedifferentresultsobtained. Fortype2nonproliferativeIMTMeyer-ter-Vehn [4] foundfurthertypicalchangeswithretinalatrophyand intraretinalcystsonOCT.Sigler [1] reportedalsoremain ofinnerretinalcystsandadisruptedfovealouternuclear layer.Matt [11] reportedamoderatemorphologicaleffect ofIVBsbutsomeindividualpatientsexperiencealong-term benefit.Thissupportsourfinding,thatOCTthicknesswas notrelevantforvisualoutcomebutratherinitialBCVAand numberofinjections. InTable1,itisshowedthatpatientswithtype2IMT receivedbettervisualimprovementthantype1patientsafter treatment.Besides,subgroupAmainlyconsistedofpatients withtype2MIT(11of18eyes)andmostpatientsin subgroupBaretype1 (7of10eyes).Thebettereffectand thefewernumberofinjectionsintype2IMTcouldmaybe suggestthatthedifferentpathogenesisofthetwotypesmay playaroletotheresponseandsensitivitytothebevacizumab treatment. Aforced(repeated)IVBinjectionsregimeforthetreatment oftype1andtype2(nonproliferative)IMTwithastrict followupandaPRNinjectionschemeshouldbeconsidered asatreatmentoptionforthepatients.Inourstudywitha forcedformofmaximal4IVBinjections(oneeveryfour week)afunctionalimprovementofthelogMARbaseline visualacuityandaslightlymorphologicalreductionofthe fovealandmaximaltemporalmacularthicknesswereseen. Thebaselinevisualacuityseemstobeanimportant predictiveindicatorforthenumberofinjectionsneeded.
